Liver/Biliary Disorders News

WASHINGTON — PXL065, a novel PPAR gamma-sparing chemical entity of pioglitazone, reduced liver fat content with no dose-dependent effect on weight gain in patients with nonalcoholic steatohepatitis, according to late-breaking data.

WASHINGTON — Elevated Z polymer levels may predict lung and liver disease activity in patients with alpha 1 antitrypsin deficiency, according to a presenter at The Liver Meeting.

WASHINGTON — Patients with alcohol use disorder and diabetes mellitus or hepatitis C were at higher risk for advanced liver disease, while African American race had a protective effect, according to late-breaking data at The Liver Meeting.

WASHINGTON — Prednisone induced a higher 90-day survival rate and lower incidence of acute kidney injury compared with anakinra and zinc sulfate in patients with severe alcohol-associated hepatitis, according to late-breaking data.

WASHINGTON — Efruxifermin improved liver histology, liver fat content and noninvasive markers of disease in patients with stage 2 or 3 fibrosis related to nonalcoholic steatohepatitis, according to late-breaking data at The Liver Meeting.

WASHINGTON — In a Healio video exclusive, Alexander G. Miethke, MD, noted that Livmarli demonstrated significant reductions in pruritus and serum bile acids across multiple subtypes of progressive familial intrahepatic cholestasis.

WASHINGTON — Patients with cirrhosis in low- or middle-income countries had an increased risk for inpatient and 30-day mortality, likely due to disparities in transplant access, according to research presented at The Liver Meeting.

WASHINGTON — Pegylated interferon alpha potentiated the antiviral activity of VIR-2218 in a small subset of noncirrhotic patients with chronic hepatitis B, according to preliminary data presented at The Liver Meeting.

WASHINGTON — Although adenovirus infection has been widely implicated in an outbreak of acute, severe hepatitis in children, data presented at The Liver Meeting found no “singular definitive etiology” for these cases.

WASHINGTON — Patients with cirrhosis who received three doses of the COVID-19 mRNA vaccine, demonstrated an 80% reduced risk for SARS-COV-2 infection, symptomatic COVID-19, and moderate/severe/critical COVID-19, noted a presenter here.